A Study of Outcomes with Rituximab Induction versus Maintenance Treatments for IgG4-Related Diseases


About this study

The purpose of this study is to compare IgG4-related disease remission and relapse rates between patients who had induction rituximab treatment with or without follow-up maintenance rituximab therapy, at Mayo Clinic, Rochester between 1 January 2000 and 22 December 2015.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Age ≥ 18 years at time of study contact
  • Received rituximab therapy for IgG4-related disease at Mayo Clinic Rochester between 1 Jan 2000 and 22 Dec 2015
  • Subject has agreed to review of medical records for research purposes

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Mark Topazian, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer